Glucuronidation of mycophenolic acid by Wistar and Mrp2-deficient TR - rat liver microsomes

Drug Metabolism and Disposition

Volumn 36, Issue 1, 2008, Pages 46-50

  Westley, Ian S ^a,c   Morris, Raymond G ^a,b   Evans, Allan M ^c   Sallustio, Benedetta C ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GLUCURONIC ACID; MULTIDRUG RESISTANCE PROTEIN 2; MYCOPHENOLATE ACYL GLUCURONIDE; MYCOPHENOLATE ETHER GLUCURONIDE; MYCOPHENOLIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME INHIBITION; ENZYME METABOLISM; GLUCURONIDATION; LIVER MICROSOME; METABOLITE; NONHUMAN; PRIORITY JOURNAL; RAT; WISTAR RAT;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; GLUCURONIDASE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HYDROLYSIS; MICROSOMES, LIVER; MYCOPHENOLIC ACID; RATS; RATS, WISTAR;

RATTUS; RATTUS NORVEGICUS;

EID: 37549030838     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.017210     Document Type: Article

References (34)

1. Bohme M, Buchler M, Muller M, and Keppler D (1993) Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett 333:193-196.
2. Bowalgaha K and Miners J (2001) The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol 52:605-609.
3. Brown N, Aw M, Mieli-Vergani G, Dhawan A, and Tredger J (2002) Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. Ther Drug Monit 24:598-606.
4. Bullingham R, Monroe S, and Nicholls A (1996a) Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after a single-dose oral and intravenous administration. J Clin Pharmacol 36:315-324.
5. Bullingham R, Nicholls A, and Hale M (1996b) Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 28:925-929.
6. Christians U and Sewing K (1995) Alternative cyclosporine metabolic pathways and toxicity. Clin Biochem 28:547-559.
7. Filler G, Lepage N, Deliste B, and Mai I (2001) Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients. Ther Drug Monit 23:514-519.
8. Gregoor P, De Sevaux R, Hene R, Hesse C, Hilbrands L, Vos P, van Gelder T, Hoitsma A, and Weimar W (1999) Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 68:1603-1606.
9. Hesselink D, van Hest R, Mathot R, Bonthuis F, Weimar W, de Bruin R, and van Gelder T (2005) Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 5:987-994.
10. Jager W, Gehring E, Hagenauer B, Aust S, Senderowicz A, and Thalhammer T (2003) Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: role of multidrug resistance protein 2 (Mrp2). Life Sci 72:2841-2854.
11. Jager W, Sartori M, Herzog W, and Thalhammer T (1998) Genistein metabolism in liver microsomes of wistar and mutant TR(-) rats. Res Commun Mol Path Pharmacol 100:105-116.
12. Johnson B, Zhang P, Schuetz J, and Brouwer K (2006) Characterization of transport protein expression in multidrug resistance-associated protein (MRP) 2-deficient rats. Drug Metab Dispos 34:556-562.
13. Kobayashi M, Saitoh H, Kobayashi M, Tadano K, Takahashi K, and Hirano T (2004) Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 309:1029-1035.
14. Kuypers D, Vanrenterghem Y, Squifflet J, Mourad M, Abramowicz D, Oellerich M, Armstrong V, Shipkova M, and Daems J (2003) Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 25:609-622.
15. Lin JH and Lu AYH (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361-390.
16. Liu K, Kim M, Jung W, Kang W, Cha I, and Shin J (2005) Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner. Drug Metab Dispos 33:209-213.
17. Miles K, Stern S, Smith P, Kessler F, Ali S, and Ritter J (2005) An investigation of human and rat liver microsomal mycophenolic acid glucuronidation: evidence for a principle role of UGT1A enzymes and species differences in UGT1A specificity. Drug Metab Dispos 33:1513-1520.
18. Miners J, Smith P, Sorich M, McKinnon R, and Mackenzie P (2004) Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44:1-25.
19. Newton D, Wang R, and Evans D (2005) Determination of phase 1 metabolic enzyme activities in liver microsomes of Mrp2 deficient TR- and EHBR rats. Life Sci 77:1106-1115.
20. Ngui J, Chen Q, Shou M, Wang R, Stearns R, Baillie T, and Tang W (2001) In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4′- and 10-hydroxywarfarin. Drug Metab Dispos 29:877-886.
21. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, and Marquet P (2005) Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase 2 metabolism. Drug Metab Dispos 33:139-146.
22. Sesink A, Arts I, de Boer V, Breedveld P, Schellens J, Hollman P, and Russel F (2005) Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. Mol Pharmacol 67:1999-2006.
23. Shipkova M, Armstrong V, and Wieland E (1999) Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Clin Pharmacol 126:1075-1082.
24. Shipkova M, Wieland E, Schutz E, Weise C, Niedmann P, Oellerich M, and Armstrong V (2001) The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc 33:1080-1081.
25. Shitara Y, Itoh T, Sato H, Li A, and Sugiyama Y (2003) Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610-616.
26. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier P, Itoh T, and Sugiyama Y (2002) Comparative inhibitory effects of different compounds on rat Oatp1 (Slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res 19:147-153.
27. Soroka C, Lee J, Azzaroli F, and Boyer J (2001) Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology 33:783-791.
28. Strassburg C, Barut A, Obermayer-Strauss P, Li Q, Nguyen N, Tukey R, and Manns M (2001) Identification of cyclosporine A and tacrolimus glucuronidation in human and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferases: UGT2B7. J Hepatol 34:865-872.
29. Webb B, Mardon K, Wright A, Prasad S, Addison R, and Dickinson R (2003) Hepatic disposition of harmol and its conjugates in Wistar and Mrp2 transporter-deficient TR- rats. Proc Aust Soc Clin Exp Pharmacol Toxicol 10:A96.
30. Westley I, Brogan L, Morris R, Evans A, and Sallustio B (2006) Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. Drug Metab Dispos 34:261-266.
31. Westley I, Sallustio B, and Morris R (2005) Validation of a high performance liquid chromatography method for the measurement of mycophenolic acid and its glucuronide metabolites in plasma. Clin Biochem 38:824-829.
32. Williams J, Ring B, Cantrell V, Campanale K, Jones D, Hall S, and Wrighton S (2002) Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos 30:1266-1273.
33. Zanger U, Vilbois F, Hardwick J, and Meyer U (1988) Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry 27:5447-5454.
34. Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A, and Miller J (1999) Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 21:35-43.